Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Assets: 2020-2025

Historic Return on Assets for Insight Molecular Diagnostics (IMDX) over the last 3 years, with Sep 2025 value amounting to -1.30%.

  • Insight Molecular Diagnostics' Return on Assets fell 70.00% to -1.30% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.30%, marking a year-over-year decrease of 70.00%. This contributed to the annual value of -1.11% for FY2024, which is 108.00% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Return on Assets of -1.30% as of Q3 2025, which was down 12.85% from -1.15% recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Return on Assets ranged from a high of -0.20% in Q2 2021 and a low of -1.30% during Q3 2025.
  • In the last 3 years, Insight Molecular Diagnostics' Return on Assets had a median value of -0.60% in 2023 and averaged -0.84%.
  • Its Return on Assets has fluctuated over the past 5 years, first rose by 12bps in 2021, then crashed by 72bps in 2024.
  • Over the past 5 years, Insight Molecular Diagnostics' Return on Assets (Quarterly) stood at -0.41% in 2021, then dropped by 4bps to -0.45% in 2022, then climbed by 1bps to -0.43% in 2023, then crashed by 72bps to -1.16% in 2024, then tumbled by 70bps to -1.30% in 2025.
  • Its Return on Assets stands at -1.30% for Q3 2025, versus -1.15% for Q2 2025 and -1.23% for Q1 2025.